Abstract
Background: Toxic optic neuropathies (TONs) often present with a gradual and bilateral decrease in visual acuity, scotomas and optic disc pallor. Obtaining an accurate history is the critical first step in determining the etiology of TONs.
Methods: This updated review contains a thorough analysis of the current PubMed-indexed literature on the most common agents responsible for TONs, including methanol, ethambutol, amiodarone, linezolid, tumor necrosis factor alpha inhibitors and phosphodiesterase 5 inhibitors. Results: The reviewed articles are mainly case reports presenting new and controversial aspects of the above agents. New treatment strategies, such as erythropoietin for methanol optic neuropathy, are being proposed for TONs, a condition that was previously regarded as untreatable. Conclusion: TONs could cause significant disability due to visual impairment. In case of early diagnosis and drug withdrawal, most TONs are treatable. Patients need to be appropriately counseled, and prescribing physicians should be especially made aware of TON-inducing medications.Keywords: Amiodarone, ethambutol, linezolid, methanol, phosphodiesterase 5 inhibitors, toxic optic neuropathy, tumor necrosis factor alpha inhibitors.
Current Pharmaceutical Design
Title:An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies
Volume: 23 Issue: 4
Author(s): Weronika Wasinska-Borowiec, Kaveh Abri Aghdam, Jukka Matias Saari and Andrzej Grzybowski
Affiliation:
Keywords: Amiodarone, ethambutol, linezolid, methanol, phosphodiesterase 5 inhibitors, toxic optic neuropathy, tumor necrosis factor alpha inhibitors.
Abstract: Background: Toxic optic neuropathies (TONs) often present with a gradual and bilateral decrease in visual acuity, scotomas and optic disc pallor. Obtaining an accurate history is the critical first step in determining the etiology of TONs.
Methods: This updated review contains a thorough analysis of the current PubMed-indexed literature on the most common agents responsible for TONs, including methanol, ethambutol, amiodarone, linezolid, tumor necrosis factor alpha inhibitors and phosphodiesterase 5 inhibitors. Results: The reviewed articles are mainly case reports presenting new and controversial aspects of the above agents. New treatment strategies, such as erythropoietin for methanol optic neuropathy, are being proposed for TONs, a condition that was previously regarded as untreatable. Conclusion: TONs could cause significant disability due to visual impairment. In case of early diagnosis and drug withdrawal, most TONs are treatable. Patients need to be appropriately counseled, and prescribing physicians should be especially made aware of TON-inducing medications.Export Options
About this article
Cite this article as:
Wasinska-Borowiec Weronika, Aghdam Abri Kaveh, Saari Matias Jukka and Grzybowski Andrzej, An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies, Current Pharmaceutical Design 2017; 23 (4) . https://dx.doi.org/10.2174/1381612823666170124113826
DOI https://dx.doi.org/10.2174/1381612823666170124113826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Low - Molecular Weight Heparins and Unfractionated Heparins during Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Bayes Syndrome and Imaging Techniques
Current Cardiology Reviews Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Diabetes-Induced Alterations in Renal Medullary Microcirculation and Metabolism
Current Diabetes Reviews Review of Recent Patents on Foldable Ventricular Assist Devices
Recent Patents on Biomedical Engineering (Discontinued) The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Radiocontrast Nephropathy: Progress not Prevention
Current Cardiology Reviews Endogenous Ligand Bias by Chemokines: Implications at the Front Lines of Infection and Leukocyte Trafficking
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Role of Cytochrome P450 Metabolites of Arachidonic Acid in Hypertension
Current Drug Metabolism Protein Interaction Networks in Metallo Proteins and Docking Approaches of Metallic Compounds with TIMP and MMP in Control of MAPK Pathway
Letters in Drug Design & Discovery Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk
Current Drug Abuse Reviews